Novel Opioid Receptor Agonists with Reduced Morphine-like Side Effects

Area of Science:

• Pharmacology
• Medicinal Chemistry
• Neuroscience

Background:

• Opioid analgesics, like morphine, are crucial for managing moderate to severe pain.
• However, their clinical utility is limited by significant side effects, including abuse liability, respiratory depression, and gastrointestinal issues.
• Developing safer analgesics that retain efficacy while minimizing adverse effects is a major unmet medical need.

Purpose of the Study:

• This review discusses innovative approaches to dissociate opioid analgesics from their detrimental side effects.
• It highlights recent research focused on developing safer pain management strategies.
• The aim is to provide an overview of novel therapeutic avenues for opioid-related adverse effects.

Main Methods:

• Review of recent scientific literature on novel opioid analgesic development.
• Discussion of strategies targeting G protein-coupled receptors (GPCRs) and their signaling pathways.
• Focus on biased agonism, positive allosteric modulation, and multi-agonist approaches for opioid receptor subtypes.

Main Results:

• Biasing G protein-coupled receptors (GPCRs) away from β-arrestin2 recruitment shows promise (e.g., TRV130, PZM21, HS665).
• Positive allosteric modulators of the mu-opioid receptor (MOR), such as BMS-986122, offer an alternative therapeutic strategy.
• Development of multiple agonists for opioid receptor subtypes (e.g., SNC80, DPI-125) is also explored.

Conclusions:

• Emerging therapeutic strategies show potential for disconnecting opioid analgesia from adverse effects.
• Targeting specific signaling pathways and receptor interactions offers a path toward safer pain relief.
• Further research into MOR and β-arrestin2 interactions is key to developing next-generation analgesics.